Kia ora Ms Faulkner,

Please find a response to your request attached to this email.

Kind regards,

Gendi McFadyen| Government Services Advisor
Te Pātaka Whaioranga | Pharmac
PO Box 10-254, Wellington 6140 | Level 9, 40 Mercer Street, Wellington 6011
P: 0800 660 050 | www.pharmac.govt.nz

-----Original Message-----
From: Ms Faulkner <[FOI #22091 email]>
Sent: Monday, 13 March 2023 3:30 pm
To: Web Enquiry <[email address]>
Subject: Official Information request - Funding for Ixekizumab

[You don't often get email from [FOI #22091 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

I am requesting information about the funding of Ixekizumab (brand name Taltz).

Specifically, I would like to know if:

a) This medication is currently being considered for funding, has been considered for funding in the past, or if there is any indication it will be considered in the near future?

b) If the medication is being considered for funding, I would like to know which autoimmune conditions it is being considered as a treatment option for.

Yours faithfully,
Ms Faulkner

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #22091 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://aus01.safelinks.protection.outlo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://aus01.safelinks.protection.outlo...

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections